HR Pharmaceuticals and Poiesis Medical Sign a Deal for Dual Balloon Catheter Technology in North America
Shots:
- HR Pharmaceuticals and Poiesis Medical have signed an exclusive commercialization agreement for the latter’s Dual Balloon Catheter (Duette) technology
- As per the agreement, HR Pharmaceuticals obtains exclusive rights to commercialize the product in North America for addressing AEs associated with Foley catheterization, necessary for specific patient populations
- The company anticipates the processing of Duette Dual Balloon Catheters orders from Jan 2, 2024 onwards
Ref: PR Newswire | Image: HR Pharmaceuticals
Related News:- YL Biologics Reports the NDA Submission of YLB217 (biosimilar product of long-acting erythropoiesis stimulating agent Nesp)
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
